Literature DB >> 12697903

Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma.

Nicole Y Fang1, Timothy C Greiner, Dennis D Weisenburger, Wing C Chan, Julie M Vose, Lynette M Smith, James O Armitage, R Aeryn Mayer, Brian L Pike, Francis S Collins, Joseph G Hacia.   

Abstract

Mutations have been described in the ataxia telangiectasia mutated (ATM) gene in small numbers of cases of lymphoid neoplasia. However, surveys of the ATM mutation status in lymphoma have been limited due to the large size (62 exons) and complex mutational spectrum of this gene. We have used microarray-based assays with 250,000 oligonucleotides to screen lymphomas from 120 patients for all possible ATM coding and splice junction mutations. The subtypes included were diffuse large B cell, mantle cell, immunoblastic large B cell, follicular, posttransplant lymphoproliferative disorder, and peripheral T cell lymphoma. We found the highest percentage of ATM mutations within the mantle cell (MCL) subtype (43%, 12 of 28 cases), followed by a lower level (10% of cases) in the other subtypes. A frame-shift ATM mutation was found in one peripheral T cell lymphoma patient. In six MCL cases examined, four ATM variants were due to somatic mutation in the tumor cells whereas two others seemed to be germ-line in origin. There was no difference in p53 mutation status in the ATM mutant and wild-type groups of MCL. There was no statistically significant difference in the median overall survival of patients with wild-type vs. mutated ATM in MCL. Additional mutational and functional analyses are needed to determine whether ATM mutations contribute to the development and progression of MCL or are just the consequence of genomic instability in MCL.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12697903      PMCID: PMC154352          DOI: 10.1073/pnas.0831102100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  48 in total

1.  High-throughput methods for detection of genetic variation.

Authors:  V N Kristensen; D Kelefiotis; T Kristensen; A L Børresen-Dale
Journal:  Biotechniques       Date:  2001-02       Impact factor: 1.993

Review 2.  Molecular cytogenetics.

Authors:  N J Carpenter
Journal:  Semin Pediatr Neurol       Date:  2001-09       Impact factor: 1.636

Review 3.  DNA methylation: a profile of methods and applications.

Authors:  Mario F Fraga; Manel Esteller
Journal:  Biotechniques       Date:  2002-09       Impact factor: 1.993

Review 4.  Ataxia telangiectasia gene mutations in leukaemia and lymphoma.

Authors:  J Boultwood
Journal:  J Clin Pathol       Date:  2001-07       Impact factor: 3.411

5.  ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma.

Authors:  Kirsten Grønbaek; Jesper Worm; Elisabeth Ralfkiaer; Vibeke Ahrenkiel; Peter Hokland; Per Guldberg
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

6.  Mutation of the ATM gene is not involved in the pathogenesis of either follicle center lymphoma or its transformation to higher-grade lymphoma.

Authors:  Izidore S Lossos; Yvonne R Thorstenson; Tierney L Wayne; Peter J Oefner; Ronald Levy; Gilbert Chu
Journal:  Leuk Lymphoma       Date:  2002-05

Review 7.  Mantle cell lymphoma: a biological and therapeutic paradigm.

Authors:  Didier Decaudin
Journal:  Leuk Lymphoma       Date:  2002-04

8.  Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells.

Authors:  Sara Ek; Carl-Magnus Högerkorp; Michael Dictor; Mats Ehinger; Carl A K Borrebaeck
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

Review 9.  Clinical translation of gene expression profiling in lymphomas and leukemias.

Authors:  Andreas Rosenwald; Louis M Staudt
Journal:  Semin Oncol       Date:  2002-06       Impact factor: 4.929

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  32 in total

Review 1.  The molecular pathology of primary immunodeficiencies.

Authors:  Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  J Mol Diagn       Date:  2004-05       Impact factor: 5.568

2.  Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy.

Authors:  Kenneth L Pitter; Dana L Casey; Yue C Lu; Margaret Hannum; Zhigang Zhang; Xinmao Song; Isabella Pecorari; Biko McMillan; Jennifer Ma; Robert M Samstein; Isaac X Pei; Atif J Khan; Lior Z Braunstein; Luc G T Morris; Christopher A Barker; Andreas Rimner; Kaled M Alektiar; Paul B Romesser; Christopher H Crane; Joachim Yahalom; Michael J Zelefsky; Howard I Scher; Jonine L Bernstein; Diana L Mandelker; Britta Weigelt; Jorge S Reis-Filho; Nancy Y Lee; Simon N Powell; Timothy A Chan; Nadeem Riaz; Jeremy Setton
Journal:  J Natl Cancer Inst       Date:  2021-03-01       Impact factor: 13.506

Review 3.  DNA damage response and hematological malignancy.

Authors:  Masatoshi Takagi
Journal:  Int J Hematol       Date:  2017-04-03       Impact factor: 2.490

4.  Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-cell lymphoma.

Authors:  Michelle J Lee; Jean L Koff; Jeffrey M Switchenko; C Ileen Jhaney; R Andrew Harkins; Sharvil P Patel; Sandeep S Dave; Christopher R Flowers
Journal:  Cancer       Date:  2020-05-29       Impact factor: 6.860

Review 5.  Molecular diagnosis in lymphoma.

Authors:  Adam Bagg
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

Review 6.  Cancer driver mutations in protein kinase genes.

Authors:  Ali Torkamani; Gennady Verkhivker; Nicholas J Schork
Journal:  Cancer Lett       Date:  2008-12-10       Impact factor: 8.679

7.  ATM mediates cytotoxicity of a mutant telomerase RNA in human cancer cells.

Authors:  Bradley A Stohr; Elizabeth H Blackburn
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

Review 8.  B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies.

Authors:  José P Vaqué; Nerea Martínez; Ana Batlle-López; Cristina Pérez; Santiago Montes-Moreno; Margarita Sánchez-Beato; Miguel A Piris
Journal:  Haematologica       Date:  2014-02       Impact factor: 9.941

Review 9.  Emerging common themes in regulation of PIKKs and PI3Ks.

Authors:  Harri Lempiäinen; Thanos D Halazonetis
Journal:  EMBO J       Date:  2009-09-24       Impact factor: 11.598

10.  Monoketone analogs of curcumin, a new class of Fanconi anemia pathway inhibitors.

Authors:  Igor Landais; Sanne Hiddingh; Matthew McCarroll; Chao Yang; Aiming Sun; Mitchell S Turker; James P Snyder; Maureen E Hoatlin
Journal:  Mol Cancer       Date:  2009-12-31       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.